PFE - Pfizer Inc.

NYSE - NYSE Delayed price. Currency in USD
44.37
-0.13 (-0.29%)
At close: 4:02PM EDT

44.20 -0.17 (-0.38%)
After hours: 6:05PM EDT

Stock chart is not supported by your current browser
Previous close44.50
Open44.44
Bid44.21 x 4000
Ask44.50 x 1000
Day's range44.02 - 44.51
52-week range33.20 - 45.81
Volume17,103,310
Avg. volume20,844,756
Market cap260.102B
Beta (3Y monthly)0.84
PE ratio (TTM)11.85
EPS (TTM)3.74
Earnings date30 Oct 2018
Forward dividend & yield1.36 (3.06%)
Ex-dividend date2018-11-08
1y target est42.94
Trade prices are not sourced from all markets
  • Pfizer (PFE) Stock Moves -0.29%: What You Should Know
    Zacks1 hour ago

    Pfizer (PFE) Stock Moves -0.29%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.37, marking a -0.29% move from the previous day.

  • Pfizer: Analysts’ Recommendations on October 22
    Market Realist5 hours ago

    Pfizer: Analysts’ Recommendations on October 22

    Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.

  • Pfizer: Analysts Expect Revenue Growth in Q3
    Market Realist6 hours ago

    Pfizer: Analysts Expect Revenue Growth in Q3

    As we discussed earlier, analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to revenues of $13.2 billion during the third quarter of 2017. The revenue growth is expected to be driven by innovative health products’ strong performance.

  • Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
    Market Realist6 hours ago

    Pfizer’s Third-Quarter Earnings: Analysts’ Estimates

    Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.

  • What’s Pfizer’s Current Valuation?
    Market Realist3 days ago

    What’s Pfizer’s Current Valuation?

    In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).

  • Pfizer’s Dividends and Earnings Quality
    Market Realist3 days ago

    Pfizer’s Dividends and Earnings Quality

    In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist3 days ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Pfizer’s Growth Rate and Estimates
    Market Realist4 days ago

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

  • What Are Pfizer’s Revenue Drivers?
    Market Realist4 days ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist4 days ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist4 days ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • Analyzing Pfizer’s Stock Performance in October
    Market Realist4 days ago

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.

  • Is Sangamo Therapeutics Inc. a Buy?
    Motley Fool5 days ago

    Is Sangamo Therapeutics Inc. a Buy?

    Can this beaten-down gene-editing and gene therapy biotech bounce back?

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Fool5 days ago

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • Top Research Reports for Pfizer, Caterpillar & Charter Communications
    Zacks5 days ago

    Top Research Reports for Pfizer, Caterpillar & Charter Communications

    Top Research Reports for Pfizer, Caterpillar & Charter Communications

  • Pfizer (PFE) Gains But Lags Market: What You Should Know
    Zacks6 days ago

    Pfizer (PFE) Gains But Lags Market: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $43.92, marking a +1.86% move from the previous day.

  • Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
    Yahoo Finance6 days ago

    Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional

    The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.

  • What Nektar Therapeutics’ Valuation Trend Indicates
    Market Realist6 days ago

    What Nektar Therapeutics’ Valuation Trend Indicates

    In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist6 days ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.

  • How Analysts View Merck Stock, Pre-Q3 Results
    Market Realist6 days ago

    How Analysts View Merck Stock, Pre-Q3 Results

    Between October 11 and 12, Merck (MRK) stock rose ~2.11% from $68.37 to close at $69.81. It was 32% higher than its 52-week low of $52.83 on April 3. Merck’s 52-week high is $72.89, reached on October 10.

  • US wants drug prices in TV ads: 'Patients deserve to know'
    Associated Press7 days ago

    US wants drug prices in TV ads: 'Patients deserve to know'

    TRENTON, N.J. (AP) — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials.

  • Trump's Drug-Ad Price Shaming Won't Fix the Problem
    Bloomberg7 days ago

    Trump's Drug-Ad Price Shaming Won't Fix the Problem

    A series of tweets earlier this year managed to push pharmaceutical companies including Pfizer Inc. to temporarily halt price increases. Donald J. Trump @realDonaldTrump Pfizer & others should be ashamed that they have raised drug prices for no reason. The tactic is being taken to a new level with the administration’s plan, officially revealed Monday afternoon by Health and Human Services Secretary Alex Azar, to force drugmakers to disclose the list price of medicines available under Medicare or Medicaid in their TV ads. The main issue with the proposed rule is that a drug’s list or sticker price is very far from what many people or their health-care plans actually pay.

  • Merck’s Operating Expenditure and Recent Developments
    Market Realist7 days ago

    Merck’s Operating Expenditure and Recent Developments

    Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.

  • What’s Expected for Merck’s Q3 2018 Earnings
    Market Realist7 days ago

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.